Overview

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Status:
Terminated
Trial end date:
2016-07-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Neurocrine Biosciences
Takeda
Collaborator:
Takeda